Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma: Three case reports. Issue 32 (August 2019)

• Record Type: Journal Article
• Authors: Chen, Chen; Liu, Song-Ran; Zhou, Shu; Li, Xiao-Hui; Wang, Xiao-Hui; Tao, Ya-Lan; Chang, Hui; Zhang, Wen-Wen; Li, Wen-Fei; Zhou, Si-Lang; Xia, Yun-Fei
• Other Names: NA. section editor.
• Is Part Of: Medicine. Volume 98:Issue 32(2019)
• Publication Date: 2019-08
• Subjects: antiangiogenic agent -- combined therapy -- endostar -- objective response rate -- refractory nasopharyngeal carcinoma; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000016592
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Rationale: Refractory nasopharyngeal carcinoma is challenging to treat and at present there is no standard treatment or any good choice. Patient concerns: Although the three patients in our case reports had already underwent multiple treatments before, they still suffered from disease recurrence of nasopharyngeal carcinoma. Diagnosis: They were diagnosed as refractory nasopharyngeal carcinoma. Interventions: A continuous infusion of Endostar, an antiangiogenic agent, combined with chemotherapy and radiation therapy was given to treat the patients. Outcomes: Patients showed complete or partial response to the combined therapy as evidenced by regression of tumors and decrease in plasma Epstein–Barr virus (EBV) DNA load. Lessons: Continuous infusions of Endostar in combination with chemotherapy and/or radiation therapy showed promising efficacy and safety. The combination therapy indicates a new approach to treat refractory nasopharyngeal carcinoma.